Dr. Rosenberg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5841 S. MARYLAND
M/C 2115
Chicago, IL 60637Phone+1 773-702-6149Fax+1 773-702-3163
Summary
- I am Assistant Professor of Medicine at the University of Chicago. My academic interest is in developing novel therapeutic strategies for patients with head and neck cancer. As a clinical investigator, I develop and conduct clinical trials for patients with head and neck cancer. My particular focus is incorporating novel therapeutics and immunotherapeutic strategies for the treatment of head and neck cancer, as well as developing strategies to reduce treatment-related toxicity.
Education & Training
McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2016 - 2019
University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 2013 - 2016
Tel Aviv University SacklerClass of 2013, MD
University of Illinois at Urbana-ChampaignBS, Chemistry, Music, Cum Laude, 2004 - 2008
Certifications & Licensure
IL State Medical License 2015 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy Start of enrollment: 2019 Jan 16
- Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer Start of enrollment: 2020 Oct 01
- A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer Start of enrollment: 2022 Oct 17
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized C...Ari J Rosenberg, Aditya Juloori, Michael J Jelinek, Nishant Agrawal, John F Cursio
JAMA Oncology. 2025-03-06 - Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas.Hanna M Hieromnimon, Anna Trzcinska, Frank T Wen, Frederick M Howard, James M Dolezal
Oral Oncology. 2025-03-04 - Reply to: Enfortumab Vedotin: A Promising Therapy for Head and Neck Cancer With Potential Links to Human Papillomavirus.Paul L Swiecicki, Emrullah Yilmaz, Ari Joseph Rosenberg, Takao Fujisawa, Justine Yang Bruce
Journal of Clinical Oncology. 2025-02-19
Press Mentions
Chemo-Immunotherapy Approach Shows Potential Benefit in Patients with Advanced HPV-Negative Head and Neck CancerMarch 6th, 2025- Chemo-Immunotherapy Exhibits Promising Efficacy in Advanced HPV-Negative Head and Neck Cancer PatientsMarch 6th, 2025
- Clearance of Circulating Tumor HPV-DNA, Monitored Using HPV-SEQ, Predicts Improved Survival: A JAMA Oncology PublicationAugust 27th, 2024
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
